Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byron Jones

Pharmaceutical statistics

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|May 4, 2007
A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug developmentScott D Patterson, Byron Jones
Pharmaceutical Statistics|December 14, 2011
Viewpoint: observations on scaled average bioequivalenceScott D Patterson, Byron Jones
Pharmaceutical Statistics|February 10, 2018
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parametersJohanna Mielke, Heike Woehling, Byron Jones
Pharmaceutical Statistics|March 21, 2012
Fitting E(max) models to clinical trial dose-response dataSimon Kirby, Phil Brain, Byron Jones
Pharmaceutical Statistics|December 29, 2018
Properties of the weighted log-rank test in the design of confirmatory studies with delayed effectsJosé L Jiménez, Viktoriya Stalbovskaya, Byron Jones
Pharmaceutical Statistics|October 27, 2018
Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databasesAndrew Bate, Christy Chuang-Stein, Andrew Roddam, et al.
Pharmaceutical Statistics|May 23, 2022
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence studyByron Jones, Bingbing Li, Morten Bagger, et al.
Pharmaceutical Statistics|January 4, 2012
Statistical approaches for conducting network meta-analysis in drug developmentByron Jones, James Roger, Peter W Lane, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|May 4, 2007
A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug developmentScott D Patterson, Byron Jones
Pharmaceutical Statistics|December 14, 2011
Viewpoint: observations on scaled average bioequivalenceScott D Patterson, Byron Jones
Pharmaceutical Statistics|February 10, 2018
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parametersJohanna Mielke, Heike Woehling, Byron Jones
Pharmaceutical Statistics|March 21, 2012
Fitting E(max) models to clinical trial dose-response dataSimon Kirby, Phil Brain, Byron Jones
Pharmaceutical Statistics|December 29, 2018
Properties of the weighted log-rank test in the design of confirmatory studies with delayed effectsJosé L Jiménez, Viktoriya Stalbovskaya, Byron Jones
Pharmaceutical Statistics|October 27, 2018
Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databasesAndrew Bate, Christy Chuang-Stein, Andrew Roddam, et al.
Pharmaceutical Statistics|May 23, 2022
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence studyByron Jones, Bingbing Li, Morten Bagger, et al.
Pharmaceutical Statistics|January 4, 2012
Statistical approaches for conducting network meta-analysis in drug developmentByron Jones, James Roger, Peter W Lane, et al.
Pageof 1